Ltd4 is a lipid of Fatty Acyls (FA) class. Ltd4 is associated with abnormalities such as Inflammatory Bowel Diseases, Inflammatory disorder, Asthma, Pneumonia and Allergic asthma. The involved functions are known as inhibitors, Signal Transduction, Cell Survival, antagonists and Phosphorylation. Ltd4 often locates in Membrane, Tissue membrane, Protoplasm, Cytoplasmic matrix and membrane fraction. The associated genes with LTD4 are ALOX5 gene, UMOD gene, P4HTM gene, RAF1 gene and Homologous Gene. The related lipids are Lipopolysaccharides.
To understand associated biological information of LTD4, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
LTD4 is suspected in Asthma, Inflammatory Bowel Diseases, Inflammatory disorder, Pneumonia, Allergic asthma, Virus Diseases and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with LTD4
Lipid pathways are not clear in current pathway databases. We organized associated pathways with LTD4 through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Weiss SR et al. | Quenching: inhibition of development and expression of amygdala kindled seizures with low frequency stimulation. | 1995 | Neuroreport | pmid:8595196 |
Tang SS et al. | Leukotriene D4 induces cognitive impairment through enhancement of CysLT₠R-mediated amyloid-β generation in mice. | 2013 | Neuropharmacology | pmid:22982445 |
Kang KH et al. | Protection of dopaminergic neurons by 5-lipoxygenase inhibitor. | 2013 | Neuropharmacology | pmid:23800665 |
Conroy DM et al. | Relaxant effects of pituitary adenylate cyclase activating polypeptide (PACAP) on epithelium-intact and -denuded guinea-pig trachea: a comparison with vasoactive intestinal peptide (VIP). | 1995 | Neuropeptides | pmid:8538872 |
Dudek SM and Friedlander MJ | Developmental down-regulation of LTD in cortical layer IV and its independence of modulation by inhibition. | 1996 | Neuron | pmid:8663986 |
Schuhmann MU et al. | Temporal profiles of cerebrospinal fluid leukotrienes, brain edema and inflammatory response following experimental brain injury. | 2003 | Neurol. Res. | pmid:12866196 |
Wang XY et al. | Leukotriene D4 induces amyloid-β generation via CysLT(1)R-mediated NF-κB pathways in primary neurons. | 2013 | Neurochem. Int. | pmid:23318673 |
Lynch KR et al. | Characterization of the human cysteinyl leukotriene CysLT1 receptor. | 1999 | Nature | pmid:10391245 |
Zhao L et al. | The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. | 2004 | Nat. Med. | pmid:15322539 |
Capra V et al. | Identification and characterization of two cysteinyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma. | 1998 | Mol. Pharmacol. | pmid:9547367 |
Kargman S et al. | Protein kinase C-dependent regulation of sulfidopeptide leukotriene biosynthesis and leukotriene C4 synthase in neutrophilic HL-60 cells. | 1994 | Mol. Pharmacol. | pmid:8190095 |
Sarau HM et al. | Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999 | Mol. Pharmacol. | pmid:10462554 |
Ravasi S et al. | A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. | 2000 | Mol. Pharmacol. | pmid:10825389 |
Nothacker HP et al. | Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. | 2000 | Mol. Pharmacol. | pmid:11093801 |
Campos MR et al. | Differential kinase requirement for enhancement of Fc gammaR-mediated phagocytosis in alveolar macrophages by leukotriene B4 vs. D4. | 2009 | Mol. Immunol. | pmid:19223078 |
Shi ZZ et al. | Disruption of gamma-glutamyl leukotrienase results in disruption of leukotriene D(4) synthesis in vivo and attenuation of the acute inflammatory response. | 2001 | Mol. Cell. Biol. | pmid:11463821 |
Bellamkonda K et al. | The impact of inflammatory lipid mediators on colon cancer-initiating cells. | 2015 | Mol. Carcinog. | pmid:25154976 |
Capra V et al. | Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. | 2007 | Med Res Rev | pmid:16894531 |
Kurogi Y | Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. | 2003 | Med Res Rev | pmid:12424751 |
Forsell PK et al. | Metabolism of anandamide into eoxamides by 15-lipoxygenase-1 and glutathione transferases. | 2012 | Lipids | pmid:22684912 |